



The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study

Raj K.S. Badhan^{a,*}, Rosalind Gittins^b, Dina Al Zabit^a

^a Medicines Optimisation Research Group, Aston Pharmacy School, Aston University, Birmingham, B4 7ET, United Kingdom

^b Addiction, 67-69 Cowcross St., London EC1M 6PU, United Kingdom

ARTICLE INFO

Keywords:

Methadone
Pharmacokinetics
PBPK
Rifampicin
Dose
Optimization

ABSTRACT

Background: The use of oral methadone in opioid substitution treatment (OST) for the management of opioid use disorder is established clinical practice. Confounding treatment is the increased risks of contracting *Mycobacterium tuberculosis*, the mainstay treatment of which incorporates the potent CYP 2B6 inducer rifampicin. **Methods:** This study applied pharmacokinetic modelling using virtual clinical trials, to pharmacokinetically quantify the extent and impact of rifampicin-mediated drug-drug interactions (DDI) on methadone plasma concentrations. An R-methadone model was developed and validated against 11 retrospective clinical studies prior to use in all subsequent studies. The aims were to investigate: (i) the impact of the DDI on daily methadone doses of 60 mg, 90 mg and 120 mg; (ii) dose escalation during rifampicin and (iii) dose reduction following rifampicin cessation.

Results: A dose increase to 160 mg daily during rifampicin treatment phases was required to maintain peak methadone plasma concentrations within a derived therapeutic window of 80–700 ng/mL. Dose escalation prior to rifampicin initiation was not required and resulted in an increase in subjects with supra-therapeutic concentrations. However, during rifampicin cessation, a dose reduction of 10 mg every 2 days commencing prior to rifampicin cessation, ensured that most patients possessed a peak methadone plasma concentration within an optimal therapeutic window.

Implications: Rifampicin significantly alters methadone plasma concentrations and necessitates dose adjustments. Daily doses of almost double those used perhaps more commonly in clinical practice are required for optimal plasma concentration and careful consideration of dose reduction strategies would be required during the deinduction phase.

1. Introduction

Opioid use disorder remains an ongoing challenge worldwide, with over 17 million people currently thought to be using heroin (Degenhardt et al., 2016). Some of the latest data for England estimates that 257,476 people aged 15–64 are using opiates (Hay et al., 2017). Seventy five percent of those who engage with drug treatment services seek support for opiates and particularly for problems with heroin, according to Public Health England data (Burkinshaw et al., 2017).

The use of oral methadone in opioid substitution treatment (OST) for the management of opioid use disorder is established clinical practice and is supported by a robust evidence base (Lingford-Hughes et al., 2012; National Institute for Clinical Excellence, 2007; World Health Organisation, 2015). Doses are typically initiated at 10–30 mg/day, increasing by up to 5–10 mg/day (to a maximum of 30 mg above

the initial dose in the first week), then optimized with incremental changes every few days, aiming for the usual therapeutic range of 60–120 mg/day. When appropriate, doses are reduced at a rate that is tailored to the individual, for example by 5 mg every one to two weeks in the community setting (Public Health England, 2017).

Methadone is an isomeric mixture of R-Methadone and S-Methadone, where R-methadone is thought to be the clinical active moiety with at least 10 times higher affinity for opioid receptors μ (MOR) and δ (DOR) than the S-isomer (Callahan et al., 2004). The elimination of methadone is primarily mediated by hepatic Cytochrome P450 biotransformation, followed by renal excretion. Its *in-vitro* biotransformation is mediated by CYP 2B6, 2C9 and 3A4 (Foster et al., 1999; Gadel et al., 2015). However, its clinical biotransformation is primarily mediated through CYP2B6-mediated N-demethylation (Chang et al., 2011; Kharasch, 2017; Kharasch and Stubbert, 2013;

* Corresponding author at: Life and Health Sciences Aston Pharmacy School, Aston University Birmingham, B4 7ET, United Kingdom.

E-mail address: r.k.s.badhan@aston.ac.uk (R.K.S. Badhan).

<https://doi.org/10.1016/j.drugalcdep.2019.03.013>

Received 8 January 2019; Received in revised form 28 February 2019; Accepted 18 March 2019

Available online 20 May 2019

0376-8716/ © 2019 Elsevier B.V. All rights reserved.




Fig. 1. A work-flow based approach to methadone pharmacokinetic modelling.

Total et al., 2008).

Given that CYP 2B6 is a highly inducible CYP isozyme (Code et al., 1997; Gadel et al., 2015), this may partly contribute to the wide inter-individual variability in metabolic clearance, which necessitates doses being tailored to individuals over a relatively wide therapeutic range (Rostami-Hodjegan et al., 1999). However, of particular concern is the possibility of patients being treated with concomitant medication that can directly inhibit or induce the CYP 2B6, such as rifampicin, phenytoin, efavirenz and macrolides (Wolff et al., 1993).

Nearly 2 billion people are infected worldwide with tuberculosis (TB) (Glaziou et al., 2009), and within the European region recent reports have suggested an incidence of 32 per 100,000 population (World Health Organization, 2017). People who inject opioids are at increased risk of being infected with latent *Mycobacterium tuberculosis* (TB) and/or human immunodeficiency virus (HIV) (Centers for Disease Control, 1989), and progression may be accelerated in this group (Antonucci et al., 1995; Markowitz et al., 1997; Selwyn et al., 1989, 1992). A recent review has highlighted that the prevalence of TB in people who are using illicit substances can be as high as 59% (Deiss et al., 2009) and that epidemiological factors that are common in this group (alcohol and tobacco use, homelessness and incarceration) can increase the risk of TB infection (Barclay et al., 1995; Drobniewski et al., 2005; Hudolin, 1975; Nelson et al., 1995). The mainstay treatment for TB treatment is a fixed-dose combination of medication which usually includes rifampicin.

Rifampicin is a highly potent inducer of CYP 2B6 (Faucette et al., 2004; Kenny et al., 2018) and is a common cause of many diverse drug-drug interactions (DDIs) (Pea and Furlanut, 2001; Venkatesan, 1992), particularly when used at common doses for TB treatment (600 mg once daily for 6 months) (World Health Organization, 2010). However, few reports have specifically examined the interaction of rifampicin with methadone from a pharmacokinetic/pharmacodynamics perspective (Dedicoat, 2012; Kreek et al., 1976; Raistrick et al., 1996), and where this was investigated a reduction in methadone plasma concentrations by 35–65% was reported (Baciewicz and Self, 1984; Kreek et al., 1976; Niemi et al., 2003), resulting in a delayed onset and an increased potential for opioid withdrawal symptoms (Niemi et al., 2003).

Given that CYP 2B6 enzyme induction is a time-dependent process (Code et al., 1997; Dedicoat, 2012), the clinical impact of the interaction may not be immediately apparent prior to attainment of a new steady-state enzyme protein/activity levels. Further, given that many patients may be stabilized on maintenance doses of methadone over many years, the (relatively) short period of rifampicin exposure would necessitate careful dose adjustment during the rifampicin-mediated CYP 2B6 induction and de-induction phases of enzyme activity. However, knowledge of how to conduct methadone dose adjustment under these circumstances are currently lacking.

We have previously applied pharmacokinetic modelling to explore rifampicin-mediated DDI with antimalarial agents and to optimization antimalarial dosing strategies (Olafuyi et al., 2017a, b). In this study we develop a robust predictive pharmacokinetic model to assess drug interactions between methadone and rifampicin through the application of virtual clinical trials simulations. Further, the model we proposed is developed from an extensive and robust application of retrospective clinical pharmacokinetics data of methadone use in patients.

The primary aim of this study was to propose clinically appropriate methadone dose adjustment necessary for patients undergoing concomitant rifampicin treatment during methadone maintenance therapy. The objectives of this study were to: (i) develop a robust and validated pharmacokinetic model for R-methadone; (ii) identify a suitable therapeutic window for enantiomeric methadone and (iii) explore the impact of rifampicin on R-methadone pharmacokinetics at different stages of methadone dosing for OST.

2. Methods

Population based PBPK modelling was conducted using the virtual clinical trials simulator Simcyp (Simcyp Ltd, a Certara company, Sheffield, UK, Version 16). Simulations incorporated mixed genders (50:50) unless otherwise stated. A four-stage workflow approach was applied for the development, validation and simulation of methadone (Fig. 1).

The default Simcyp validated adult Healthy Volunteer (HV) population groups were used in simulations for Steps 1-4. The latter

population group accounted for ontogenic related changes in physiological/biochemical parameters such as organ volumes, organ perfusion and drug metabolising enzymes (Johnson, 2005, 2008; Small et al., 2017). Further, the Simcyp population groups account for population variability through the inclusion of a variability metric (% coefficient variability) which was established from public health databases such as the US National Health and Nutrition Examination Survey (<https://www.cdc.gov/nchs/nhanes/>).

2.1. Step 1: model development and validation

A full description of the model development can be found in Section 1 of the Supplementary materials. Initial model development considered six clinical studies where R- and S-methadone was dosed as single oral doses of 11 mg (9.9 mg methadone base) (Dale et al., 2004; Kharasch et al., 2012a, 2008; Kharasch et al., 2009a, b; Totah et al., 2008), and where each study reported enantiomer specific pharmacokinetics. Model refinement was subsequently conducted using a study reported by Bruce et al. (2013) in patients stabilized on a maintenance dose of 80–120 mg daily for at least 2 weeks. Model refinement incorporated methadone-mediated auto-induction of CYP 2B6 and CYP 3A4 (Campbell et al., 2013), and are detailed Supplementary materials Section 1.

Model validation was conducted using: (i) a study reported by Garimella et al (2015) where patients were stabilized for at least 28 days on doses of between 40 mg and 120 mg daily; (ii) a study reported by Jamois et al (2009) where single daily oral doses of 60–120 mg were used in which patients had been stabilized for 3 months and taking the same dose for at least 2 weeks prior to the study; (iii) refinements to metabolic clearance were assessed against available clinical studies which reported enantiomer specific DDIs between efavirenz and methadone (Kharasch et al., 2012b) and the impact of CYP2B6 polymorphisms on enantiomer specific methadone pharmacokinetics (Kharasch et al., 2015).

In all cases, model simulations were run to match the reported age range, patient number and gender ratio as reported by each study. In the absence of this information, a default trial size of 100 subjects (10 × 10 design) aged 20–50 years old and with equal numbers of males and females. For genotype validation studies, populations were simulated as entirely wild-type (*1/*1) or polymorphic (*6/*6) through modification of the default CYP phenotype frequency within the Simcyp Healthy Volunteer population group. Where multiple doses were administered, a dose escalation strategy was implemented, commencing at 20 mg once daily and escalated in weekly intervals by 20 mg to the required dose, unless otherwise stated. Simulations were run to ensure that the analysis was conducted when the methadone plasma concentration had reached steady-state. In all simulations, the free base form was modelled based upon a salt-to-base conversion ratio of 0.894 (U.S. Department of Justice, 2018). The final enantiomer specific methadone parameters that were applied to all subsequent steps are detailed in Table S1 of the Supplementary materials. In all subsequent studies, the R- enantiomer was considered.

To ensure optimized methadone dosing, knowledge of a therapeutic window was required. The dose range of 60–120 mg resulted in a reported therapeutic plasma concentration within the range of 80–250 ng/mL for the R-enantiomer and 80–400 ng/mL for the R,S-enantiomer mix (Eap et al., 2000; Gamaleya et al., 1999). Further, the application of receiver operating characteristics (ROC) was able to identify optimal therapeutic thresholds, with an upper range spanning 200–250 ng/mL for R-methadone and 400–500 ng/mL for R,S-methadone (Hallinan et al., 2006). Other studies have reported ranges of between 150–700 ng/mL for enantiomeric methadone with doses spanning 3–100 mg daily (Wolff et al., 1991).

Further, it can be difficult to clearly distinguish the overlap between potentially fatal methadone plasma/blood concentrations when the person is in receipt of optimized OST. For example, a report from

Australia (Pilgrim et al., 2013) identified a median blood methadone concentration of 500 ng/mL (range: 100–3000 ng/mL) associated with 206 deaths of people using heroin from 2001 to 2005, although it was not possible to definitively confirm exactly what was consumed prior to death in the context of ‘on-top’ use compared to what may have been prescribed. Further, Karch and Stephens (2000) identified a mean blood concentration of methadone as ≥ 800 ng/mL in 38 patients who were believed to have died from methadone overdose.

Given that in non-fatality reports, enantiomeric methadone plasma concentration ranges span 80–700 nm/mL, and in fatality cases plasma concentration ranges span > 500 –800 ng/mL, simulations in subsequent steps defined a therapeutic window with a lower therapeutic limit of 80 ng/mL and upper limit set at 700 ng/mL.

2.2. Step 2: impact of co-initiation of rifampicin and methadone OST on methadone pharmacokinetics

Building upon Step 1, the DDI between methadone and rifampicin was assessed over 365 days using a scenario wherein 100 subjects (10 × 10 design) were initiated on R-methadone with a 20 mg daily dose. The initial 20 mg dose was followed by dose escalation, based on weekly 20 mg dose adjustments up to maintenance doses of 60 mg, 90 mg or 120 mg until the end of the study, in line with current UK national guidelines for methadone initiation and monitoring requirements (Public Health England, 2017). In conjunction, rifampicin was orally dosed at 600 mg once daily commencing on day 1 and terminating on day 168. The impact of the resultant DDI on methadone plasma concentrations, and the location of the C_{max} within the therapeutic window was analyzed.

2.3. Step 3: adjusting methadone dose following the termination of rifampicin

Building upon Step 2, the DDI between methadone and rifampicin was simulated over 365 days using a scenario wherein 100 subjects (10 × 10 design) were initiated on R-methadone with a 20 mg daily dose followed by dose escalation with 20 mg dose adjustments each week up to maintenance dose of 160 mg. In conjunction, rifampicin was orally dosed at 600 mg once daily commencing on day 1 and terminating on day 168.

In order to identify an appropriate methadone dose reduction strategy upon completion of rifampicin, dose regimen optimization was carried out to assess the impact of: (i) a shorter dose reduction period (10 mg every four days, versus three days and versus two days) and (ii) the consequence of dose reduction implemented 1 week prior to rifampicin termination.

In all cases, an optimized dose reduction strategy was considered when most subjects achieved a peak methadone plasma concentration within the therapeutic window. For all subsequent steps, the R-enantiomer was considered.

2.4. Step 4: adjusting methadone dose during the commencement and termination of rifampicin

Building upon Step 3, this step assessed the impact of initiating rifampicin during an existing maintenance phase of methadone OST. Methadone was initiated with a 20 mg daily dose followed by dose escalation with 20 mg dose adjustment each week up to 90 mg daily. On day 84 rifampicin was initiated at a dose of 600 mg for a period of 168 days (terminating on day 252).

During initiation of rifampicin treatment, methadone dose regimen optimization was considered through increasing the methadone dose by 10 mg every 2 days commencing on (i) day 84 onwards and (ii) commencing prior to rifampicin, from day 74 onwards. Within each dosing regimen, methadone doses were escalated to 160 mg daily.

Immediately after the termination of rifampicin (day 252),




Fig. 2. Simulated median plasma concentration-time profile of R-methadone for 60 mg, 90 mg and 120 mg daily doses in the absence and presence of rifampicin.

R-methadone was orally administered and dose escalated by 20 mg each week to a final daily dose of 60–120 mg the absence (A) and presence (B) of 600 mg once daily oral rifampicin from days 1–168 ($n = 100$). Solid lines represent median predicted plasma concentration-time profile for each dose. The upper-most line represents the 95th percentile for the 120 mg dose and lower-most line represents 5th percentile for the 60 mg dose. The shaded area represents the range of the therapeutic window.

methadone dose adjustments were further made to maintain plasma concentrations within the mid-point of the therapeutic window, and utilized the optimized dosing regimen identified in Step 3 for this deinduction phase.

2.5. Predictive performance

In simulations for Step 1, a prediction to within two-fold (0.5–2-fold) of the mean published clinical data was generally accepted as part of the ‘optimal’ predictive performance (Ginsberg et al., 2004; Prieto Garcia et al., 2018; Tylutki et al., 2018).

2.6. Visual predictive checks

Model predictions in step 1 were compared to existing clinical studies using a visual predictive checking (VPC) strategy. This approach was described at the 2012 FDA Pediatric Advisory Committee (US Food and Drug Administration, 2012) (U.S. Food and Drug Administration, 2012). The predictability of the simulations was validated by comparing the predicted 5th and 95th percentiles (along with mean or median) of predicted concentration–time profiles (generated from Simcyp) against the observed data for any validation data sets. Where predicted data points largely overlapped with those from the observed data sets, which should contain (where possible) some measure of spread of observed plasma concentration data (e.g., a standard deviation for each mean concentration point), the prediction was assumed to be valid.

2.7. Data and statistical analysis

The observed data from clinical studies that were used for visual predictive checks were extracted using WebPlotDigitizer v.3.10 (<http://arohatgi.info/WebPlotDigitizer/>). Where a DDI was simulated, the model performance was principally dictated by the comparison of the AUC ratio or C_{max} ratio (ratio of the AUC or C_{max} in the absence and presence of the inhibitor or inducer). An AUC ratio or C_{max} ratio greater

than 1.25 indicates an inhibition reaction whereas a ratio of less than 0.8 indicates an induction reaction whilst a ratio of between 0.8–1.25 indicates no interaction. Where applicable, statistical analysis was conducted using paired t-tests with a $P < 0.05$ indicating statistical significance.

3. Results

3.1. Step 1: model development and validation

An R- and S- enantiomer methadone file was developed and validated against a range of published clinical studies using the Simcyp Healthy Volunteer population group (See Section 2.1). For all single dose and multi-dose studies, the predicted R-methadone and S-methadone plasma concentration-time profiles were successfully predicted to within the observed range for each study and model-predicted t_{max} , C_{max} , and AUC were predicted to within 2-fold of the reported parameters for each study, confirming successful validation. For all subsequent studies, R-methadone was used. Details of all validation results can be found in the Supplementary materials Section 2.

3.2. Step 2: impact of co-initiation of rifampicin and methadone OST on methadone pharmacokinetics

To assess the impact of a rifampicin-mediated DDI on methadone pharmacokinetics, three doses of methadone were investigated (60 mg, 90 mg and 120 mg), covering the low, middle and higher end of the established therapeutic dose range (Fig. 2).

At the lowest daily dose of 60 mg daily, in the absence of rifampicin (Fig. 2A), steady state plasma methadone was attained on day 18 with a mean C_{max} of 230.81 ng/mL \pm 99.09 ng/mL (Table 1 and Fig. 3). In the presence of rifampicin (Fig. 2B), the resultant methadone steady-state mean C_{max} (quantified on day 50) was significantly reduced ($P < 0.0001$) to 85.50 ng/mL \pm 43.37 ng/mL with a concomitant decrease in mean AUC from 212.11 ng/mL.d in the absence of rifampicin to 69.11 ng/mL.d in the presence of rifampicin ($AUC_{ratio} = 0.33 \pm 0.1$)

Table 1
Summary of the predicted R-methadone pharmacokinetics following dose escalation to 60 mg, 90 mg and 120 mg in the absence and presence of rifampicin.

		Day 50 ^a											End of Study			
		No Rifampicin						Rifampicin					No Rifampicin			
		AUC (ng/mL.d)	t _{max} (d)	C _{max} (ng/mL)	C _{min} (ng/mL)	AUC _{inh} (ng/mL.d)	t _{max,inh} (d)	C _{max,inh} (ng/mL)	C _{min,inh} (ng/mL)	AUC Ratio	C _{max} Ratio	C _{min} Ratio	AUC (ng/mL.d)	t _{max} (d)	C _{max} (ng/mL)	C _{min} (ng/mL)
60 mg daily	Mean	212.11	0.22	230.81	187.83	69.11	0.2	85.5	50.77	0.33	0.38	0.27	376.67	0.22	230.88	142.84
	Median	196.29	0.21	216.48	175.09	57.15	0.2	72.91	41.5	0.32	0.36	0.26	351.34	0.21	216.5	135.9
	SD	96.1	0.03	99.09	91.49	39.87	0.03	43.37	35.63	0.1	0.1	0.1	32.24	0.15	31.2	4.06
	Min	23.95	0.15	31.2	14.56	18.02	0.14	24.53	9.16	0.15	0.18	0.1	893.21	0.31	516.18	368.79
	Max	486.23	0.31	515.98	446.72	255.29	0.3	285.9	219.36	0.75	0.79	0.68	181.68	0.03	99.17	80.12
90 mg daily	Mean	321.61	0.22	349.97	284.71	104.92	0.2	129.79	77.07	0.33	0.38	0.27	322.11	0.22	350.51	285.27
	Median	297.84	0.21	328.55	265.61	86.76	0.2	110.69	63	0.32	0.36	0.26	297.99	0.21	328.67	265.83
	SD	145.44	0.03	149.98	138.37	60.53	0.03	65.84	54.09	0.1	0.1	0.1	146.02	0.03	150.56	139.05
	Min	36.37	0.15	47.37	22.1	27.35	0.14	37.25	13.91	0.16	0.18	0.1	36.35	0.15	47.37	22.1
	Max	736.47	0.31	781.53	676.32	387.54	0.3	434	332.99	0.75	0.79	0.68	738.03	0.31	783.62	678.5
120 mg daily	Mean	426.57	0.22	464.27	377.15	139.86	0.2	173.02	102.73	0.33	0.38	0.27	429.48	0.22	467.34	380.36
	Median	395.87	0.21	437.01	352.59	115.68	0.2	147.58	84	0.32	0.36	0.26	397.32	0.21	438.23	354.44
	SD	191.68	0.03	197.72	181.93	80.64	0.03	87.72	72.03	0.1	0.1	0.1	194.69	0.03	200.74	185.4
	Min	48.49	0.15	63.16	29.46	36.47	0.14	49.66	18.55	0.16	0.18	0.1	48.47	0.15	63.16	29.46
	Max	972.4	0.31	1031.95	891.3	516.26	0.3	578.15	443.44	0.75	0.79	0.68	984.04	0.31	1044.83	904.66

^a Data collected at steady-state phase. Subscript 'inh' refers to pharmacokinetic metric in the presence of rifampicin; Max: Maximum value; Min: minimum value; SD: Standard deviation.

(Table 1 and Fig. 3).

Increasing the daily dose to 90 mg and 120 mg resulted in a corresponding increase ($P < 0.0001$) in the mean C_{max} to 129.79 ng/mL \pm 65.84 ng/mL and 173.02 ng/mL \pm 87.72 ng/mL, respectively, in the presence of rifampicin (Table 1 and Fig. 3).

Following completion of the rifampicin treatment regimen, the resultant steady-state mean C_{max} and AUC was recovered approximately 21-days post rifampicin completion, day 187, (Fig. 2 and Table 1) for all doses (Fig. 3).

At steady-state for the 60 mg dose, in the absence of rifampicin, 97% of subjects possessed a C_{max} within the therapeutic window and 3% within the sub-therapeutic ranges (See Supplementary materials Section 3: Table S8). However, in the presence of rifampicin 44% of subjects possessed a C_{max} within the therapeutic window with 56% of subjects with a sub-therapeutic C_{max} (See Supplementary materials Section 3: Table S8)⁵. With dose increase to 90 mg and 120 mg, the percentage of subjects possessing a C_{max} within the therapeutic window, in the presence of rifampicin, increased to 81% and 93% respectively. However, in the absence of rifampicin, increasing the dose to 90 mg or 120 mg resulted in a concomitant increase in the number of subjects with a supra-therapeutic C_{max}, 2% and 14% respectively (See Supplementary materials Section 3: Table S8)⁵.

3.3. Step 3: adjusting methadone dose following the termination of rifampicin

Step 2 identified that lower daily methadone dose would result in high number of subjects with sub-therapeutic peak methadone concentrations in the presence of rifampicin. This step therefore simulated the impact of a higher daily dose of 160 mg once daily, with escalation in 20 mg weekly dose intervals (Fig. 4)

In the absence of rifampicin (Fig. 4A and B), simulated steady state plasma methadone was attained on day 60 with a C_{max} of 616.19 ng/mL \pm 261.32 ng/mL (Table 2). In the presence of rifampicin (Fig. 4C and D), the resultant simulated methadone steady-state C_{max} (quantified on day 60) was significantly reduced ($P < 0.001$) to 230.56 ng/mL \pm 116.73 ng/mL with a concomitant decrease in AUC from 566.10 ng/mL.d in the absence of rifampicin to 186.36 ng/mL.d in the presence of rifampicin (AUC_{ratio} = 0.33 \pm 0.10) (Table 2). Following completion of the rifampicin treatment regimen, the resultant C_{max} and AUC

were recovered 21-days post rifampicin completion, day 201, (Fig. 4E and Table 2).

At steady-state with a 160 mg daily dose, in the absence of rifampicin, 72% of subjects possessed a C_{max} within the therapeutic window and 28% within the supra-therapeutic range. However, in the presence of rifampicin 96% of subjects possessed a C_{max} within the therapeutic window with only 1% of subjects within the supra-therapeutic range (See Supplementary materials section 3: Table S8).

Following termination of rifampicin, during the 140 mg dose reduction phase, 76% of subjects possessed a C_{max} within the therapeutic window with 22% of subjects possessing a supra-therapeutic C_{max} (See Supplementary materials section 3: Table S8)⁶. However, with a dose of 100 mg, there were still a significant number of subjects (12%) with peak methadone concentration within the supra-therapeutic range (See Supplementary materials section 3: Table S8)⁶. Further dose optimization was therefore considered.

Simulations were conducted to assess a deinduction regimen that would limit the number of subjects with sub- and supra-therapeutic peak methadone concentrations. Trial designs investigated included (i) a 10 mg dose reduction every 4, 3 or 2 days and commencing on the day of rifampicin termination (Fig. 5A) and (ii) a dose reduction commencing 1 week prior to rifampicin termination from the optimal dose reduction strategy identified in (i) (Fig. 5B).

All proposed dose reduction approaches resulted in a significant percentage of subjects remaining within the sub- and supra-therapeutic regions (data not shown) (Fig. 5A). However, a reduction of dose 10 mg every 2 days, commencing one week prior to rifampicin termination (Fig. 5B), resulted in a minimal 'peak' in C_{max} observed for dose reduction initiated post-rifampicin termination on day 168 (Fig. 5A), with a mean C_{max} of 531.64 ng/mL \pm 239 ng/mL on day 168 (Table 3). Furthermore, with this optimal strategy, on day 168, 93% of subjects attained a steady-state C_{max} within the therapeutic window with no subjects within the supra-therapeutic regions (See Supplementary materials section 3: Table S8).

3.4. Step 4: adjusting methadone dose during the commencement and termination of rifampicin

Based upon results obtained in Step 3, dose optimization was conducted to identify a suitable dose escalation and reduction regiment




Fig. 3. Simulated median plasma concentration-time profile of R-methadone following doses of 60–120 mg once daily in the absence and presence of rifampicin. R-methadone was orally administered and dose escalated by 20 mg each week to a final daily dose of either 60 mg, 90 mg or 120 mg in the absence (black lines; labelled as ‘No DDI’) and presence (blue lines; labelled as ‘DDI’) of 600 mg once daily oral rifampicin from days 1–168. Dose escalation phases are indicated. Bold solid lines represent median predicted plasma concentration-time profile with lower and upper lines representing the 5th and 95th percentile respectively. The shaded area represents the range of the therapeutic window.

during rifampicin treatment. Following incremental 20 mg weekly dose escalation (Fig. 6A) to achieve a final daily dose of 90 mg, in the absence of rifampicin (Fig. 6B), simulated steady state plasma methadone was attained on day 33 with a mean C_{max} (as quantified on day 80) of $359.85 \text{ ng/mL} \pm 152.48 \text{ ng/mL}$ (Table 4). During this phase 97% of subjects achieved a C_{max} within the therapeutic window, with 2% within the supra-therapeutic region (See Supplementary materials Section 3: Table S8)⁷.

Rifampicin was initiated on day 84. However, the impact of a dose escalation in methadone was considered by increasing dose by 10 mg every 2 days commencing on day 84 onwards and increasing to 160 mg daily (Fig. 6D). Further, the impact of commencing this dose escalation prior to commencement of rifampicin was considered by a similar dose escalation commencing on day 74 (Fig. 6D). When commencing dose escalation prior to rifampicin initiation, methadone plasma concentrations peaked within the supra-therapeutic regions (Fig. 6D) on day 84. Therefore, methadone dose-escalation prior to the commencement of rifampicin was not considered as part of the optimal dosing regimen design and dose escalation was commenced on the day of rifampicin initiation (Fig. 6D). Under these conditions, simulated methadone plasma concentrations decreased over 7 days until a new steady state concentration had been attained on day 97. On day 100, methadone C_{max} had significantly reduced ($P < 0.001$) to $234.36 \text{ ng/mL} \pm 120.03 \text{ ng/mL}$ with a resultant AUC ratio of 0.34 ± 0.10 and C_{max} ratio of 0.39 ± 0.10 (Supplementary materials Section 4: Table

S9). During this phase 94% of subjects attained a C_{max} within the therapeutic window (in the presence of rifampicin) (See Supplementary materials Section 3: Table S8)⁷. Further, during this steady-state period, the highest individual C_{max} reported during the rifampicin treatment phase was 577 ng/mL (Supplementary materials Section 4: Table S9)⁸. Rifampicin treatment terminated on day 252. However, dose reduction took place 1 week prior to this commencing on day 245, reducing by 10 mg in 2 day intervals to 90 mg daily (Fig. 6E). On day 252, the impact of this dose reduction prior to stopping rifampicin resulted in a decrease in C_{max} to $176.9 \text{ ng/mL} \pm 92.47 \text{ ng/mL}$ (supplementary materials section 4: Table S10), with the lowest individual C_{max} of 50.06 ng/mL (Supplementary materials section 4: Table S10)⁹. However, at the end of the study period, methadone plasma concentration had recovered to similar levels as those reported on Day 80 (Table 4). During this dose reduction phase, on day 252 the number of subjects achieving a C_{max} within the therapeutic window was 95% with 1% demonstrating supra-therapeutic concentrations (See Supplementary materials section 3: Table S8)⁷.

4. Discussion

Oral methadone is a widely used medication for OST both nationally and internationally (Herget, 2005; Public Health England, 2017). To ensure successful treatment outcomes, dose optimization is critical in ensuring both sub-therapeutic (withdrawal symptoms/cravings) and




Fig. 4. The impact of methadone dose-escalation and dose-reduction to counter a rifampicin-mediated DDI: rifampicin initiation during methadone initiation. R-methadone was orally administered and dose escalated by 20 mg each week to a final daily dose of 160 mg the absence (A and B) and presence (C–E) of 600 mg once daily oral rifampicin from days 1–168. (D) and (E) illustrate dose escalation in the presence of rifampicin and dose reduction following the termination of rifampicin treatment, respectively. ($n = 100$). Bold/solid lines represent median predicted plasma concentration-time profile with lower and upper lines representing 5th and 95th percentile range. For Fig. 4E the percentiles are only illustrated for simulations in the presence of rifampicin). (Black: absence of rifampicin; Blue: presence of rifampicin). The shaded area represents the range of the therapeutic window.

supra-therapeutic (overdose/toxicity) effects are limited. The understanding of methadone pharmacokinetics is limited but wide inter- and intra-individual variability exists (Boulton et al., 2001). Such variability is important to consider, given that only 1 in 5 individuals receiving OST have optimized doses and some may require even higher doses (> 200 mg daily) to achieve stabilization (D'Aunno et al., 2014; Kreek et al., 2010). Part of this variability may be attributed to individual patient polymorphisms at methadone metabolism enzymes, particularly for CYP 2B6 (Mouly et al., 2015). Additionally, clinically relevant DDIs may occur with concomitant medication such as rifampicin, which is typically used for managing TB, which people who inject opioids are at

high risk of contracting (Begre et al., 2002; Ferrari et al., 2004). As a potent CYP 2B6 inducer, rifampicin can pose particular difficulties when attempting to optimize methadone doses when initiating or terminating rifampicin (Kreek et al., 1976).

This study implemented an exemplar dosing approach in line with current UK guidelines (Public Health England, 2017), with the goal of attempting to better characterize the potential impact of rifampicin on methadone plasma concentrations in order to better understand the necessary methadone dose adjustment requirements (e.g. ‘how soon?’ and ‘how quick?’), through the application of pharmacokinetic modelling and simulated virtual clinical trials. We adopted a work-flow based

Table 2
Summary of the predicted R-methadone pharmacokinetics following dose escalation and dose reduction, in the absence and presence of rifampicin.

	Day 60											End of Study			
	No Rifampicin				Rifampicin							No Rifampicin			
	AUC (ng/mL.d)	t _{max} (d)	C _{max} (ng/mL)	C _{min} (ng/mL)	AUC _{inh} (ng/mL.d)	t _{max,inh} (d)	C _{max,inh} (ng/mL)	C _{min,inh} (ng/mL)	AUC Ratio	C _{max} Ratio	C _{min} Ratio	AUC (ng/mL.d)	t _{max} (d)	C _{max} (ng/mL)	C _{min} (ng/mL)
Mean	566.10	0.22	616.19	499.89	186.36	0.20	230.56	136.83	0.33	0.38	0.27	323.31	0.22	351.82	286.34
Median	525.81	0.21	580.46	467.69	154.23	0.20	196.66	111.99	0.32	0.36	0.26	299.10	0.21	329.90	266.82
SD	253.32	0.03	261.32	240.02	107.29	0.03	116.73	95.75	0.10	0.10	0.10	146.56	0.03	151.12	139.57
Min	64.65	0.15	84.21	39.28	48.63	0.14	66.21	24.73	0.16	0.18	0.10	36.49	0.15	47.54	22.18
Max	1286.29	0.31	1365.14	1177.18	686.98	0.30	769.35	589.64	0.75	0.79	0.68	740.78	0.31	786.54	681.03

Subscript ‘inh’ refers to pharmacokinetic metric in the presence of rifampicin; Max: Maximum value; Min: minimum value; SD: Standard deviation.




Fig. 5. The impact of dose optimization during the deinduction phase.

R-methadone was orally administered and dose escalated by 20 mg each week to a final daily dose of 160 mg to day 168. Rifampicin was dosed from day 1–168 at 600 mg once daily. (A) The impact of methadone dose reduction on plasma concentration profiles from day 168 onwards with a 10 mg every 2 (green), 3 (red) or 4 (yellow) day reduction or 10 mg every 2 days commencing 1 week prior to termination of rifampicin; (B) the proposed optimal dose reduction strategy (10 mg decrease every 2 days) commencing 1 week prior to termination of rifampicin. (n = 100). Thick solid lines represent median predicted plasma concentration-time profile. For (A), the upper most faint lines represent the 95th percentile for each dose optimization strategy (5th percentiles are not shown for these). The lower-most faint line represents the 5th percentile for the ‘two day reduction at 1 week prior’ dosing strategy. For (B) the median and 95th and 5th percentiles are illustrated. The shaded area represents the range of the therapeutic window.




Table 3

Summary of the predicted R-methadone pharmacokinetics following dose escalation and dose reduction on day 168 using an optimized dosing regimen.

Day 168 (Optimized)				
No Rifampicin				
	AUC (ng/mL.d)	t _{max} (d)	C _{max} (ng/mL)	C _{min} (ng/mL)
Mean	489.48	0.21	531.64	434.00
Median	456.16	0.21	491.67	399.84
SD	231.85	0.03	239.00	220.12
Min	50.01	0.15	65.08	30.60
Max	1153.14	0.29	1222.85	1058.84

Max: Maximum value; Min: minimum value; SD: Standard deviation.

modelling approach with robust model development and refinement using retrospective clinical studies reporting methadone pharmacokinetics. Thereafter, the question of the development of clinically appropriate methadone dose adjustments in rifampicin-mediated DDIs was investigated using virtual clinical trials simulations.

4.1. Step 1: model development and validation

In Step 1, we adapted an existing Simcyp derived model for methadone and conducted robust validation tasks: 6 single dose studies, 3 multi-dose studies, 1 DDI study and 1 DDI study with consideration of CYP 2B6 single nucleotide polymorphism (SNPs). In all simulations, the predicted R-methadone and S-methadone plasma concentration-time profiles were within the range reported within each clinical study with associated predictions of C_{max}, t_{max} and AUC to within 2-fold of that reported for all studies (See Supplementary materials Sections 1 and 2).

4.2. Step 2: impact of Co-initiation of rifampicin and methadone OST on methadone pharmacokinetics

Rifampicin is known to induce CYP 2B6 and therefore this step explored the impact of this DDI at methadone daily dose ranges of 60 mg, 90 mg and 120 mg. In all cases, the impact of rifampicin was evident during the 168 day treatment period, with lower simulated steady-state peak plasma C_{max} and AUC (and both demonstrating dose dependent increases) in the presence of rifampicin (Table 1). A similar reduction in methadone plasma concentrations by 35–65% has been reported in other studies (Baciewicz and Self, 1984; Kreek et al., 1976; Niemi et al., 2003), and where the consequence of this change was reported to be a delayed onset of methadone action and an increased potential for opioid withdrawal symptoms (Niemi et al., 2003). This was confirmed, in our simulations, by the number of subjects with simulated peak methadone concentrations below the therapeutic window in the presence of rifampicin (56%) when compared to the absence of rifampicin (3%) at the lowest dose of 60 mg daily (See Supplementary materials Section 3: Table S8). A dose increase to 120 mg daily resulted in 93% of subjects within the therapeutic window (Fig. 2B). However, there still remained 7% of subjects with sub-therapeutic methadone levels. Therefore, a clear dose increase in such situations would directly benefit the majority of subjects whilst not significantly increasing the number of subjects with potentially toxic effects (See Supplementary materials Section 3: Table S8). At the termination of rifampicin, methadone plasma concentrations recovered within 25 days (Fig. 2B), a process mediated by CYP 2B6 deinduction. Despite the relatively short half-life of rifampicin (3–4 h), the regulation of the expression of CYP 2B6 protein (and subsequently degradation rates) are time-dependent processes and is therefore likely to be the primary cause for the time-dependent deinduction. For example, in a previous study examining DDI between rifampicin and midazolam, the clearance of midazolam took 2–4 week to recover to baseline, with the authors estimating the deinduction half-life in this case to be approximately 7–8 days (Reitman

et al., 2011). Other studies have also reported a similar time-scale. For example, rifampicin-induced reduction of propranolol attained steady-state concentrations within 10 days and returned to baseline within 20 days (Branch and Herman, 1984). Similarly, the return to baseline for prednisolone, following rifampicin induction, took 14 days (Lee et al., 1993).

4.3. Step 3: adjusting methadone dose following the termination of rifampicin

As demonstrated in Section 4.2, following the termination of rifampicin, the deinduction of CYP 2B6 is a time-dependent process. This step therefore focused on approaches to dose-optimize during this deinduction phase. Having established the importance of increasing daily doses during rifampicin treatment phases, the maintenance dose was increased to 160 mg daily during the 168 day rifampicin phase.

In the absence of rifampicin, this resulted in a mean simulated C_{max} of 616.19 ng/mL ± 261.32 ng/mL, with the largest individual C_{max} of 1365.14 ng/mL, placing this significantly outside of the therapeutic window (Table 2 and Fig. 4A). This was further confirmed with 28% of subjects possessing a C_{max} outside of the upper therapeutic window (See Supplementary materials Section 3: Table S8). In the presence of rifampicin, the mean C_{max} of 230.56 ng/mL ± 116.73 ng/mL was within the therapeutic window and resulted in 96% of subjects residing within this window range with only 3% of subjects with sub-therapeutic concentrations (See Supplementary materials Section 3: Table S8)¹³(Fig. 4B and C), confirming that the dose selected during this rifampicin treatment phase was suitable to ensure that most subjects would achieve methadone plasma concentration within the therapeutic window. It was, however, noted that during the deinduction phase, a 140 mg dose resulted in a significantly larger proportion, 22%, of subjects possessing peak methadone plasma concentrations outside of the therapeutic window (See Supplementary Materials section 3: Table S8)¹³(Fig. 4D), so further dose optimization around this deinduction phase was conducted (Fig. 5A). This resulted in the identification of a dose decrease of 10 mg every 2 days (to 90 mg) commencing at least 1 week prior to rifampicin termination (Fig. 5B), which ensured that the majority of subjects (93%) were within the therapeutic window range with no patients demonstrating supra-therapeutic concentrations.

Whilst very few direct studies have explored this pharmacokinetic interaction, rifampicin has been well characterized as a potent CYP 2B6 inducer (Bolt, 2004) and has also been identified as a clinical inducer by the US FDA (U.S. Food and Drug Administration, 2018). Further, a number of case reports have shown rifampicin to cause opioid withdrawal symptoms in patients taking methadone. A case report described a 40-year female taking methadone, who exhibited opioid withdrawal symptoms when starting rifampicin for tuberculosis. This caused her to not comply with her rifampicin regimen. On recommencement of her rifampicin, her methadone dose was titrated from a stabilizing dose of 50 mg (prior to TB infection) to 150 mg once daily in an inpatient setting (Raistrick et al., 1996). A further case report described withdrawal symptoms 5 days after starting rifampicin for TB (Bending and Skacel, 1977), with the patients symptoms alleviated following a methadone dose increase to 60 mg one daily. A study by Kreek et al (1976) reported that of the 87 patients on methadone who had also been taking a course of rifampicin (600 mg–900 mg daily), 30% demonstrated signs of withdrawal symptoms with reported methadone plasma concentrations that were 33–68 % lower during rifampicin treatment. Further, these withdrawal symptoms were absent in the remaining patients, whose TB was treated without rifampicin (Kreek et al., 1976). In another study, Kharasch et al. (2004) demonstrated that rifampicin decreases methadone C_{max} by 30% with an approximate 4-fold increase in clearance (Kharasch et al., 2004). Of note, however, is that this effect is not limited to methadone: similar reports have demonstrated that rifampicin co-administration with buprenorphine reduces the AUC of buprenorphine by 25% (Hagelberg et al., 2016).




Fig. 6. The impact of methadone dose-escalation and dose-reduction to counter a rifampicin-mediated DDI: rifampicin initiation during methadone maintenance. R-methadone was orally administered and dose escalated by 20 mg each week to a final daily dose of 100 mg the absence (A and B) of rifampicin. Rifampicin was initiated on day 84 at a 600 mg once daily dose and the methadone dose was increased to 160 mg daily (Figure C and D). Rifampicin was subsequently terminated on day 252 and methadone dose was reduced to 90 mg once daily from days 252–365 (E). ($n = 100$). Solid lines represent median predicted plasma concentration-time profiles with dotted lines representing 5th and 95th percentile range (Black: absence of rifampicin; Blue: presence of rifampicin). The shaded area represents the range of the therapeutic window.

Rapid dose reductions of methadone are not usually recommended unless facilitated by adjunct medication used for managing withdrawal signs and symptoms. However, our proposed schedule of dose reduction counteracts the impact of a return of CYP 2B6 levels to baseline, which would otherwise require a rapid reduction in methadone, particularly given the 25 days 'recovery' period for CYP 2B6 expression. Without reductions, individuals may achieve significantly larger C_{max} within supra-therapeutic regions which may be fatal. A slow decrease on a weekly basis would take at least 5–7 days to achieve a new steady-state concentration and therefore, a slow dose reduction (assuming a weekly basis) would be expected to take at least 1 month before standard dose ranges (60–120 mg) are achieved. In clinical practice, it is proposed that individuals receive frequent reviews and are assessed for both sub

and supra-therapeutic effects and ideally using an objective rating scale such as the Clinical Opioid Withdrawal Scale (COWS) (Wesson and Ling, 2003).

4.4. Step 4: adjusting methadone dose during the commencement and termination of rifampicin

Based upon the proposed optimal dosing adjustment, Step 4 attempted to incorporate a dose escalation and dose reduction before and after rifampicin treatment. In order to ensure that subjects were generally maintained within the therapeutic window prior to rifampicin, methadone doses were increased by 20 mg each week to 90 mg daily. During the commencement of rifampicin, we examined the possibility

Table 4

Summary of the predicted R-methadone pharmacokinetics following dose escalation and dose reduction, in the absence of rifampicin.

	Day 80				End of Study			
	No Rifampicin				No Rifampicin			
	AUC (ng/ mL.d)	t _{max} (d)	C _{max} (ng/ mL)	C _{min} (ng/ mL)	AUC (ng/ mL.d)	t _{max}	C _{max} (ng/ mL)	C _{min} (ng/ mL)
Mean	330.11	0.22	359.58	285.28	323.51	0.22	345.20	282.43
Median	330.11	0.22	359.58	285.28	323.51	0.22	345.20	282.43
SD	147.86	0.03	152.48	139.05	144.90	0.03	146.38	137.66
Min	39.00	0.15	50.86	22.10	38.22	0.15	48.83	21.88
Max	751.69	0.33	798.12	678.50	736.66	0.33	766.20	671.72

Subscript ‘inh’ refers to pharmacokinetic metric in the presence of rifampicin; Max: Maximum value; Min: minimum value; SD: Standard deviation.

of implementing methadone dose escalation on day 74 with 10 mg increments every 2 days (Fig. 6), however this resulted in a noticeable ‘peak’ in the methadone plasma concentrations in the absence of rifampicin (during days 75–84) (Fig. 6D). However, methadone dose increases at the same time as the commencement of rifampicin resulted in 94% of subjects having a peak methadone plasma concentration within the therapeutic window (See Supplementary materials section 3: Table S8), indicating optimal dosing.

During the induction process, rifampicin treatment significantly ($P < 0.001$) increases the oral clearance of methadone from 13.4 L/h in the absence of rifampicin (Supplementary materials Section 5 Figure S7)¹⁴ to 31.2 L/h following commencement of rifampicin (Supplementary materials Section 5 Figure S7). Similar reports have identified an approximate 3-fold increase in methadone clearance with concomitant rifampicin (Kreek et al., 1976; Rostami-Hodjegan et al., 1999). The induction and deinduction effects were time-dependent (Supplementary Materials Section 6 Figure S8), lasting approximately 25 days. Further, the calculated methadone deinduction half-life was 7.2 days (Supplementary materials Section 7). This may explain why a dose-adjustment prior to rifampicin commencement was not required, as the dose adjustments on day 84 onwards were sufficient to counteract the increased oral clearance of methadone following rifampicin induction (Yang et al., 2008).

In summary, methadone dose correction is required during initiation and cessation of rifampicin to directly counteract CYP 2B6 induction. The half-life of methadone and the induction time process requires consideration prior to the design of a dosing regimen to counteract the enhanced clearance of the methadone in the presence of rifampicin. Our studies demonstrated that a daily dose of 90 mg is acceptable to ensure the majority of the subjects were within the therapeutic window in the absence of rifampicin. However, during rifampicin treatment, a dose escalation to 160 mg daily may counteract the enhanced metabolic clearance of methadone and help to ensure that individuals achieve peak methadone plasma concentrations within the therapeutic window. It should be noted that although the proposed dosing regimen (during steady-state) could be conducted in a community setting, daily assessments alongside supervised consumption, or an inpatient setting may be preferable, especially if significantly high doses of methadone are thought to be required.

Although the clinical impact of rifampicin on methadone has been well established, the data presented within this study provide, for the first time, a pragmatic approach to optimize dosing of methadone in patients presented with TB. Nevertheless, the work presented requires further investigation in clinical practice to confirm our findings, however our proposed dosing range for methadone is similar to those reported previously in clinical case reports (Kreek et al., 1976; Raistrick et al., 1996).

This is important considering the epidemiological complexities associated with ‘real’ OST patient cohorts, and particularly as our

modelling approaches assume good adherence. Whilst data on adherence is relatively sparse, a medication adherence study over 8 years in China for patients enrolled on methadone-maintenance therapy identified a drop-out rate of 52% (Zhou et al., 2017). Therefore, the impact of poor adherence, particularly when individuals’ life circumstances are more chaotic, may need to be considered in the context of the simulated results presented within this study for both methadone and, more importantly, rifampicin.

It should also be noted that patients taking methadone, particularly long-term, often present with co-morbidities resulting from the individuals’ life circumstances and may require a range of pharmacological interventions with other psychotropic drugs, antibiotics, anti-convulsants and antiretroviral drugs, all of which can elicit a range of pharmacokinetic interactions (Ferrari et al., 2004). However, such co-morbidities can alter physiological processes required for methadone pharmacokinetics, for example through hepatic impairment as a result of hepatitis which may result in portal shunting and a net reduction in hepatic metabolism of methadone (Davis, 2007), or a decrease in plasma protein product resulting in an increase in free (unbound) concentration (Verbeeck, 2008). Further studies should consider the impact of additional clinical covariates on the dose adjustment requirements for similar types of DDIs in patients whom present with organ function impairment.

Furthermore, although we have provided an exemplar approach to methadone dose adjustment throughout rifampicin treatment, the quantitative outcome of our approach may initially not be easily transferrable to other non-invasive sampling methods, e.g. urine analysis. Nevertheless, utilizing robust validation approaches focused on plasma methadone levels, we have proposed the application of mechanistic pharmacokinetic modelling (through virtual clinical trial) as an approach to pragmatically assess the need for methadone dose adjustments during rifampicin treatment. This approach has the advantage of providing directly accessible clinical guidance to address the questions ‘how soon should a dose adjustment be made?’ and ‘at what frequency should this be done?’. Nevertheless, future studies should consider confirming the dosing adjustments we propose through the use of urine analysis in clinical studies.

Further, from a clinical perspective, the dose adjustment simulated during the initiation and cessation of rifampicin would require careful consideration during OST prescribing reviews, with healthcare professionals remaining vigilant during the induction and deinduction phases. Specialist treatment services should be involved in assertively engaging individuals with TB treatment and proactively encouraging adherence. When methadone dosing changes are warranted due to the addition of rifampicin, patients may be reluctant to change or concerned with change. Additionally, they may struggle to understand the need for important OST changes. These patients require careful counselling about the anticipated dose changes. Pharmacists who dispense methadone may also be able to counsel patients through changes (Public Health England, 2017). Finally, although this study focused on methadone, the potential impact of rifampicin on other OST agents such as buprenorphine is warranted (Rothman et al., 2000).

5. Conclusion

The use of rifampicin for the management of TB is common. People who inject substances are at increased risk of contracting TB and may be prescribed methadone as OST. We demonstrated an approach to conduct methadone dose correction to 160 mg, during rifampicin co-administration, in order to counter the increased methadone hepatic elimination associated CYP 2B6 induction. This study will add to the knowledge supporting prescribers in dose adjustment necessary for treating opioid addiction when faced with patients taking concomitant pharmacological inducers of methadone.

Role of funding source

None.

Contributors

RB and RG conceptualized the supervised the study. DA conducted the study. All authors participated in the article preparation, and finalized the manuscript. All authors have approved this manuscript

Conflict of interest

None.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.drugalcdep.2019.03.013>.

References

- Antonucci, G., Girardi, E., Raviglione, M.C., Ippolito, G., Almi, P., Angarano, G., Armignacco, O., Babudieri, S., Bevilacqua, N., Bini, A., 1995. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. *JAMA* 274, 143–148.
- Baciewicz, A.M., Self, T.H., 1984. Rifampin drug interactions. *Arch. Intern. Med.* 144, 1667–1671.
- Barclay 3rd, D.M., Richardson, J.P., Fredman, L., 1995. Tuberculosis in the homeless. *Arch. Fam. Med.* 4, 541–546.
- Begre, S., von Bardeleben, U., Ladewig, D., Jaquet-Rochat, S., Cosendai-Savary, L., Golay, K.P., Kosel, M., Baumann, P., Eap, C.B., 2002. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. *J. Clin. Psychopharmacol.* 22, 211–215.
- Bending, M.R., Skacel, P.O., 1977. Rifampicin and methadone withdrawal. *Lancet* 1 (8023), 1211.
- Bolt, H.M., 2004. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. *Drug Metab. Rev.* 36, 497–509.
- Boulton, D.W., Arnaud, P., DeVane, C.L., 2001. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. *Clin. Pharmacol. Ther.* 70, 48–57.
- Branch, R.A., Herman, R.J., 1984. Enzyme induction and beta-adrenergic receptor blocking drugs. *Br. J. Clin. Pharmacol.* 17 (Suppl 1), 77S–84S.
- Bruce, R.D., Winkle, P., Custodio, J.M., Wei, X., Rhee, M.S., Kearney, B.P., Ramanathan, S., Friedland, G.H., 2013. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. *Antimicrob. Agents Chemother.* 57, 6154–6157.
- Burkinshaw, P., Knight, J., Anders, P., Eastwood, B., Musto, V., White, M., Marsden, J., 2017. An Evidence Review of the Outcomes That Can Be Expected of Drug Misuse Treatment in England. Public Health England, London.
- Callahan, R.J., Au, J.D., Paul, M., Liu, C., Yost, C.S., 2004. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in *Xenopus* oocytes: stereospecific and subunit effects. *Anesth. Analg.* 98, 653–659 table of contents.
- Campbell, S.D., Crafford, A., Williamson, B.L., Kharasch, E.D., 2013. Mechanism of autoinduction of methadone N-demethylation in human hepatocytes. *Anesth. Analg.* 117, 52–60.
- Centers for Disease Control, 1989. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). *MMWR Morbid. Mortal. Wkly. Rep.* 38, 236.
- Chang, Y., Fang, W.B., Lin, S.N., Moody, D.E., 2011. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. *Basic Clin. Pharmacol. Toxicol.* 108, 55–62.
- Code, E.L., Crespi, C.L., Penman, B.W., Gonzalez, F.J., Chang, T.K., Waxman, D.J., 1997. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. *Drug Metab. Dispos.* 25, 985–993.
- D'Annunzio, T., Pollack, H.A., Frimpong, J.A., Wutchiett, D., 2014. Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels. *J. Subst. Abuse Treat.* 47, 245–250.
- Dale, O., Sheffels, P., Kharasch, E.D., 2004. Bioavailabilities of rectal and oral methadone in healthy subjects. *Br. J. Clin. Pharmacol.* 58, 156–162.
- Davis, M., 2007. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. *Clin. Pharmacokinet.* 46, 825–850.
- Dedicoat, M.J., 2012. Rifampicin reduces methadone concentrations. *BMJ* 344, e4199.
- Degenhardt, L., Stockings, E., Strang, J., Marsden, J., Hall, W.D., 2016. Illicit drug dependence. In: third edition. In: Patel, V., Chisholm, D., Dua, T., Laxminarayan, R., Medina-Mora, M.E. (Eds.), *Mental, Neurological, and Substance Use Disorders: Disease Control Priorities*, vol. 4 The World Bank, Washington, DC.
- Deiss, R.G., Rodwell, T.C., Garfein, R.S., 2009. Tuberculosis and illicit drug use: review and update. *Clin. Infect. Dis.* 48, 72–82.
- Drobniowski, F.A., Balabanova, Y.M., Ruddy, M.C., Graham, C., Kuznetsov, S.I., Gusarova, G.I., Zakharova, S.M., Melentyev, A.S., Fedorin, I.M., 2005. Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners. *Eur. Respir. J.* 26, 298–304.
- Eap, C.B., Bourquin, M., Martin, J., Spagnoli, J., Livoti, S., Powell, K., Baumann, P., Deglon, J., 2000. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. *Drug Alcohol Depend.* 61, 47–54.
- Faucette, S.R., Wang, H., Hamilton, G.A., Jolley, S.L., Gilbert, D., Lindley, C., Yan, B., Negishi, M., LeCluyse, E.L., 2004. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. *Drug Metab. Dispos.* 32, 348–358.
- Ferrari, A., Coccia, C.P., Bertolini, A., Sternieri, E., 2004. Methadone-metabolism, pharmacokinetics and interactions. *Pharmacol. Res.* 50, 551–559.
- Foster, D.J., Somogyi, A.A., Bochner, F., 1999. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. *Br. J. Clin. Pharmacol.* 47, 403–412.
- Gadel, S., Friedel, C., Kharasch, E.D., 2015. Differences in methadone metabolism by CYP2B6 variants. *Drug Metab. Dispos.* 43, 994–1001.
- Gamaleya, N., Dmitrieva, I., Borg, S., Ericsson, N., 1999. Induction of antibodies to methadone during methadone maintenance treatment of heroin addicts and its possible clinical implications. *Eur. J. Pharmacol.* 369, 357–364.
- Garimella, T., Wang, R., Luo, W.L., Wastall, P., Kandoussi, H., DeMicco, M., Bruce, R.D., Hwang, C., Bertz, R., Bifano, M., 2015. Assessment of drug-drug interactions between dactatasvir and methadone or buprenorphine-naloxone. *Antimicrob. Agents Chemother.* 59, 5503–5510.
- Ginsberg, G., Hattis, D., Russ, A., Sonawane, B., 2004. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. *J. Toxicol. Environ. Health A* 67, 297–329.
- Glaziou, P., Floyd, K., Raviglione, M., 2009. Global burden and epidemiology of tuberculosis. *Clin. Chest Med.* 30, 621–636 vii.
- Hagelberg, N.M., Fihlman, M., Hemmila, T., Backman, J.T., Laitila, J., Neuvonen, P.J., Laine, K., Olkkola, K.T., Saari, T.I., 2016. Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. *Pharmacol. Res. Perspect.* 4, e00271.
- Hallinan, R., Ray, J., Byrne, A., Agho, K., Attia, J., 2006. Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis. *Drug Alcohol Depend.* 81, 129–136.
- Hay, G., dos Santos, Anderson Rael, Swithenbank, Z., 2017. Estimates of the Prevalence of Opiate Use and/or Crack Cocaine Use, 2014/15: Sweep 11 Report. Liverpool John Moores University, Public Health Institute.
- Herget, G., 2005. Methadone and buprenorphine added to the WHO list of essential medicines. *HIV. Policy Law Rev.* 10, 23–24.
- Hudolin, V., 1975. Tuberculosis and alcoholism. *Ann. N. Y. Acad. Sci.* 252, 353–364.
- Jamois, C., Smith, P., Morrison, R., Riek, M., Patel, A., Schmitt, C., Morcos, P.N., Zhang, X., 2009. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. *Addict. Biol.* 14, 321–327.
- Johnson, T.N., 2005. Modelling approaches to dose estimation in children. *Br. J. Clin. Pharmacol.* 59, 663–669.
- Johnson, T.N., 2008. The problems in scaling adult drug doses to children. *Arch. Dis. Child.* 93, 207–211.
- Karch, S.B., Stephens, B.G., 2000. Toxicology and pathology of deaths related to methadone: retrospective review. *West. J. Med.* 172, 11–14.
- Kenny, J.R., Ramsden, D., Buckley, D.B., Dallas, S., Fung, C., Mohutsky, M., Einolf, H.J., Chen, L., Dekeyser, J.G., Fitzgerald, M., Goosen, T.C., Siu, Y.A., Walsky, R.L., Zhang, G., Tweedie, D., Hariparsad, N., 2018. Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance. *Drug Metab. Dispos.* 46, 1285–1303.
- Kharasch, E.D., 2017. Current concepts in methadone metabolism and transport. *Clin. Pharmacol. Drug Dev.* 6, 125–134.
- Kharasch, E.D., Stubbert, K., 2013. Role of cytochrome P4502B6 in methadone metabolism and clearance. *J. Clin. Pharmacol.* 53, 305–313.
- Kharasch, E.D., Hoffer, C., Whittington, D., Sheffels, P., 2004. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. *Clin. Pharmacol. Ther.* 76, 250–269.
- Kharasch, E.D., Bedynek, P.S., Park, S., Whittington, D., Walker, A., Hoffer, C., 2008. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. *Clin. Pharmacol. Ther.* 84, 497–505.
- Kharasch, E.D., Hoffer, C., Whittington, D., Walker, A., Bedynek, P.S., 2009a. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. *Anesthesiology* 110, 660–672.
- Kharasch, E.D., Walker, A., Whittington, D., Hoffer, C., Bedynek, P.S., 2009b. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. *Drug Alcohol Depend.* 101, 158–168.
- Kharasch, E.D., Bedynek, P.S., Hoffer, C., Walker, A., Whittington, D., 2012a. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). *Anesthesiology* 116, 432–447.
- Kharasch, E.D., Whittington, D., Ensign, D., Hoffer, C., Bedynek, P.S., Campbell, S., Stubbert, K., Crafford, A., London, A., Kim, T., 2012b. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. *Clin. Pharmacol. Ther.* 91, 673–684.
- Kharasch, E.D., Regina, K.J., Blood, J., Friedel, C., 2015. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. *Anesthesiology* 123, 1142–1153.

- Kreek, M.J., Garfield, J.W., Gutjahr, C.L., Giusti, L.M., 1976. Rifampin-induced methadone withdrawal. *N. Engl. J. Med.* 294, 1104–1106.
- Kreek, M.J., Borg, L., Ducat, E., Ray, B., 2010. Pharmacotherapy in the treatment of addiction: methadone. *J. Addict. Dis.* 29, 200–216.
- Lee, K.H., Shin, J.G., Chong, W.S., Kim, S., Lee, J.S., Jang, I.J., Shin, S.G., 1993. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. *Eur. J. Clin. Pharmacol.* 45, 287–289.
- Lingford-Hughes, A.R., Welch, S., Peters, L., Nutt, D.J., British Association for Psychopharmacology, E.R.G., 2012. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. *J. Psychopharmacol.* 26, 899–952.
- Markowitz, N., Hansen, N.I., Hopewell, P.C., Glassroth, J., Kvale, P.A., Mangura, B.T., Wilcosky, T.C., Wallace, J.M., Rosen, M.J., Reichman, L.B., 1997. Incidence of tuberculosis in the United States among HIV-infected persons. *Ann. Intern. Med.* 126, 123–132.
- Mouly, S., Bloch, V., Peoc'h, K., Houze, P., Labat, L., Ksouda, K., Simoneau, G., Declèves, X., Bergmann, J.F., Scherrmann, J.M., Laplanche, J.L., Lepine, J.P., Vorspan, F., 2015. Methadone dose in heroin-dependent patients: role of clinical factors, comediations, genetic polymorphisms and enzyme activity. *Br. J. Clin. Pharmacol.* 79, 967–977.
- National Institute for Clinical Excellence, 2007. Methadone and Buprenorphine for the Management of Opioid Dependence. Accessed August 2018. <https://www.nice.org.uk/guidance/ta114>.
- Nelson, S., Mason, C., Bagby, G., Summer, W., 1995. Alcohol, tumor necrosis factor, and tuberculosis. *Alcohol. Clin. Exp. Res.* 19, 17–24.
- Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J., Kivistö, K.T., 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. *Clin. Pharmacokinet.* 42, 819–850.
- Olafuyi, O., Coleman, M., Badhan, R.K.S., 2017a. The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperquine antimalarial therapy during pregnancy. *Biopharm. Drug Dispos.* 38, 464–478.
- Olafuyi, O., Coleman, M., Badhan, R.K.S., 2017b. Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: a case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. *Eur. J. Pharm. Sci.* 106, 20–33.
- Pea, F., Furlanut, M., 2001. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. *Clin. Pharmacokinet.* 40, 833–868.
- Pilgrim, J.L., McDonough, M., Drummer, O.H., 2013. A review of methadone deaths between 2001 and 2005 in Victoria, Australia. *Forensic Sci. Int.* 226, 216–222.
- Prieto Garcia, L., Janzen, D., Kanebratt, K.P., Ericsson, H., Lennernas, H., Lundahl, A., 2018. Physiologically based pharmacokinetic model of itraconazole and two of its metabolites to improve the predictions and the mechanistic understanding of CYP3A4 drug-Drug interactions. *Drug Metab. Dispos.* 46, 1420–1433.
- Public Health England, 2017. In: Department of Health and Social Care (Ed.), *Drug Misuse and Dependence: UK Guidelines on Clinical Management*. Global and Public Health.
- Raistrick, D., Hay, A., Wolff, K., 1996. Methadone maintenance and tuberculosis treatment. *BMJ* 313, 925–926.
- Reitman, M.L., Chu, X., Cai, X., Yabut, J., Venkatasubramanian, R., Zajic, S., Stone, J.A., Ding, Y., Witter, R., Gibson, C., Roupe, K., Evers, R., Wagner, J.A., Stoch, A., 2011. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. *Clin. Pharmacol. Ther.* 89, 234–242.
- Rostami-Hodjegan, A., Wolff, K., Hay, A.W., Raistrick, D., Calvert, R., Tucker, G.T., 1999. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. *Br. J. Clin. Pharmacol.* 48, 43–52.
- Rothman, R.B., Gorelick, D.A., Heishman, S.J., Eichmiller, P.R., Hill, B.H., Norbeck, J., Liberto, J.G., 2000. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. *J. Subst. Abuse Treat.* 18, 277–281.
- Selwyn, P.A., Hartel, D., Lewis, V.A., Schoenbaum, E.E., Vermund, S.H., Klein, R.S., Walker, A.T., Friedland, G.H., 1989. A prospective study of the risk of tuberculosis among intravenous drug-users with human immunodeficiency virus-infection. *N. Engl. J. Med.* 320, 545–550.
- Selwyn, P.A., Sckell, B.M., Alcabes, P., Friedland, G.H., Klein, R.S., Schoenbaum, E.E., 1992. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. *JAMA* 268, 504–509.
- Small, B.G., Wendt, B., Jamei, M., Johnson, T.N., 2017. Prediction of liver volume - a population-based approach to meta-analysis of paediatric, adult and geriatric populations - an update. *Biopharm. Drug Dispos.* 38, 290–300.
- Totah, R.A., Sheffels, P., Roberts, T., Whittington, D., Thummel, K., Kharasch, E.D., 2008. Role of CYP2B6 in stereoselective human methadone metabolism. *Anesthesiology* 108, 363–374.
- Tylutki, Z., Mendyk, A., Polak, S., 2018. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals. *J. Pharmacokinet. Pharmacodyn.* 45, 663–677.
- U.S. Department of Justice, 2018. Conversion Factors for Controlled Substances. Accessed 29th June 2018. https://www.deadiversion.usdoj.gov/quotas/conv_factor/index.html.
- U.S. Food and Drug Administration, 2012. Summary Minutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. Accessed 29th May 2018. <https://wayback.archive-it.org/7993/20170403224110/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeForPharmaceuticalScienceandClinicalPharmacology/ucm286697.htm>.
- U.S. Food and Drug Administration, 2018. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Accessed 22nd June 2018. <https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-3>.
- Venkatesan, K., 1992. Pharmacokinetic drug interactions with rifampicin. *Clin. Pharmacokinet.* 22, 47–65.
- Verbeeck, R.K., 2008. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. *Eur. J. Clin. Pharmacol.* 64, 1147–1161.
- Wesson, D.R., Ling, W., 2003. The clinical opiate withdrawal scale (COWS). *J. Psychoactive Drugs* 35, 253–259.
- Wolff, K., Sanderson, M., Hay, A.W., Raistrick, D., 1991. Methadone concentrations in plasma and their relationship to drug dosage. *Clin. Chem.* 37, 205–209.
- Wolff, K., Hay, A.W., Raistrick, D., Calvert, R., 1993. Steady-state pharmacokinetics of methadone in opioid addicts. *Eur. J. Clin. Pharmacol.* 44, 189–194.
- World Health Organization, 2015. WHO Model List of Essential Medicine. Accessed 2nd August 2018. http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_JUN2015.pdf.
- World Health Organization, 2010. Guidelines for Treatment of Tuberculosis. Accessed 2nd August 2018. <http://www.who.int/tb/publications/2010/9789241547833/en/>.
- World Health Organization, 2017. Global Tuberculosis Report. Accessed 2nd August 2018. http://www.who.int/tb/publications/global_report/en/.
- Yang, J., Liao, M., Shou, M., Jamei, M., Yeo, K.R., Tucker, G.T., Rostami-Hodjegan, A., 2008. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. *Curr. Drug Metab.* 9, 384–394.
- Zhou, K., Li, H., Wei, X., Li, X., Zhuang, G., 2017. Medication adherence in patients undergoing methadone maintenance treatment in Xi'an, China. *J. Addict. Med.* 11, 28–33.